FDA accepts NDA for Karuna’s schizophrenia treatment
November 30, 2023Medical Communications FDA, Karuna Therapeutics, NDA, Neurology, schizophrenia
Karuna Therapeutics has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for …
Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device
November 30, 2023Medical Communications Devices, FDA, Vivos Therapeutics, sleep apnea
Vivos Therapeutics has announced that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for the …
Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance
November 29, 2023Research and Development Oncology, Tolremo, clinical trial, drug resistance, solid tumours
Tolremo Therapeutics has announced that it has dosed the first patient in its first-in-human clinical trial to assess the safety, …
FDA grants breakthrough device designation to Inflammatix’s TriVerity Acute Infection and Sepsis Test System
November 29, 2023Research and Development FDA, Infections and infestations, Inflammatix, TriVerity, infection, sepsis
Inflammatix has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the company’s lead …
FDA accepts new drug application for Orexo’s opioid overdose medication
November 28, 2023Research and Development FDA, Opioid overdose, Pharmacy, opioids, orexo
Orexo has announced that its New Drug Application (NDA) for OX124 has been accepted for review by the US Food …
Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment
November 28, 2023Research and Development Arcturus Therapeutics, Chronic Diseases, FDA, ODD, cystic fibrosis
Arcturus Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ARCT-032, …
Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment
November 27, 2023Medical Communications COPD, Cardiology, Dupixent, Sanofi, clinical trial
Sanofi and Regeneron have announced results from the second investigational phase 3 NOTUS trial for Dupixent as a treatment for …
GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment
November 27, 2023Medical Communications Blenrep, GSK, Oncology, clinical trial, multiple myeloma
GSK has announced positive results from a planned interim efficacy analysis of the phase 3 DREAMM-7 head-to-head trial which assessed …
Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment
November 24, 2023Research and Development Alladapt Immunotherapeutics, Allergic Disorders, FDA, fast track designation, food allergy
Alladapt Immunotherapeutics has announced that ADP101 has received Fast Track Designation from the US Food and Drug Administration (FDA) as …
Syncona to acquire Freeline Therapeutics for $28.3m
November 24, 2023Business Services Freeline Therapeutics, Pharmacy, acquisition, syncona
Freeline Therapeutics has announced that it has entered into a definitive agreement with newly established portfolio company Syncona, in which …
Landos Biophama shares results from phase 1b trial for ulcerative colitis treatment
November 23, 2023Medical Communications Gastrointestinal tract, Landos Biopharma, clinical trial, ulcerative colitis
Landos Biopharma has announced that it has shared safety, tolerability, pharmacokinetics and clinical efficacy results for the NX-13 phase 1b …
MorphoSys shares phase 3 trial results for pelabresib in myelofibrosis treatment
November 23, 2023Research and Development Haematology, clinical trial, morphosys, myelofibrosis, pelabresib
MorphoSys has announced topline results from its phase 3 MANIFEST-2 study, which assessed pelabresib, an investigational BET inhibitor, in combination …
Genentech and NVIDIA enter AI research collaboration
November 22, 2023Research and Development AI, Genentech, Pharmacy, research collaboration
Genentech has announced that it has entered into a multi-year strategic research collaboration with NVIDIA that is intended to pair …
Merck to acquire Caraway Therapeutics for up to $610m
November 22, 2023Business Services Caraway Therapeutics, MSD, Merck, Pharmacy, acquisition
Merck (known as MSD outside of the US and Canada) and Caraway Therapeutics have announced that they have entered into …
GSK’s low carbon inhaler, Ventolin, progresses to phase 3 trialsÂ
November 21, 2023Medical Communications Asthma & COPD, GSK, Ventolin, asthma, carbon-neutral
GSK has announced that in 2024 it intends to start phase 3 trials of a low carbon version of its …
AstraZeneca launches health-tech business, Evinova
November 21, 2023Business Services AstraZeneca, Pharmacy, health-tech
AstraZeneca has announced that it has launched Evinova, its new health-tech business, which it is hoped will become a leading …
Almirall gains EC approval of Ebglyss for moderate-to-severe atopic dermatitis
November 20, 2023Medical Communications Almirall, Dermatology, Ebglyss, European Commission, atopic dermatitis
Almirall has announced that the European Commission (EC) has approved Ebglyss (lebrikizumab) for the treatment of adult and adolescent patients …
Astellas Pharma to acquire Propella Therapeutics for $175m
November 20, 2023Business Services Astellas Pharma, Oncology, Properlla Therapeutics, acquisition
Astellas Pharma and Propella Therapeutics have announced that Astellas and Propella have entered a merger agreement in which Astellas will …
FDA approves AstraZeneca’s Truqap plus Faslodex for breast cancer treatment
November 17, 2023Medical Communications AstraZeneca, FDA, Faslodex, Oncology, breast cancer
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Truqap (capivasertib) in combination with Faslodex (fullvestrant) …
FDA approves Merck’s Keytruda for gastric cancer treatment
November 17, 2023Medical Communications FDA, MSD, Merck, Oncology, gastric cancer, keytruda
Merck, known as MSD outside of the US, has announced that the US Food and Drug Administration (FDA) has approved …
Latest content
FibroFind appoints Lee Borthwick as CEO
